Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 9:26 AM ET


Company Overview of Cellerant Therapeutics, Inc.

Company Overview

Cellerant Therapeutics, Inc., a clinical stage biotechnology company, focuses on the regulation of the hematopoietic (blood-forming) system. It develops human stem cell and antibody therapies for oncology applications and blood-related disorders. The company’s pipeline products include CLT-008, an off-the-shelf cell-based therapy for the treatment of neutropenia associated with chemotherapy in oncology patients, cord blood transplantation, and acute radiation exposure; and a cancer stem cell antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. Cellerant Therapeutics, Inc. was formerly known as Celtrans, LLC. The company w...

1561 Industrial Road

San Carlos, CA 94070

United States

Founded in 2001





Key Executives for Cellerant Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 50
Chief Financial Officer
Age: 52
Senior Vice President of Regulatory, QA & Project Management
Vice President of Corporate Development
Vice President of Government Operations and Controller
Compensation as of Fiscal Year 2015.

Cellerant Therapeutics, Inc. Key Developments

Cellerant Therapeutics Inc. Appoints Rodney Young as Chief Financial Officer

Cellerant Therapeutics Inc. announced that Rodney Young has joined the Company as Chief Financial Officer. Mr. Young brings more than 25 years of financial and executive experience in the life sciences field as a chief financial officer and investment banker. Mr. Young comes to Cellerant with significant corporate finance and leadership experience. Mr. Young was previously Chief Financial Officer at StemCells, Inc.

Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients

Cellerant Therapeutics Inc. announced that patient dosing has commenced in its multi-center, open-label, randomized controlled Phase 2 clinical trial of CLT-008, a first-in-class, allogeneic, cellular therapy, in de novo acute myeloid leukemia (AML) patients receiving induction chemotherapy. The Phase 2 trial is expected to enroll up to 140 de novo AML patients 55 years of age, randomized in 1:1 ratio to either Filgrastim alone or CLT-008 single infusion plus Filgrastim. The study will evaluate the effect of CLT-008 on the duration of febrile episodes and infections related to cytarabine-based induction chemotherapy. The primary endpoint will be the duration of febrile episodes from infusion of CLT-008 to day 28. Secondary endpoints will include incidence of infection, duration of antibiotic use, incidence of mucositis, duration of hospitalization, and hematologic recovery. The Phase 2 data will guide the design and choice of endpoints for the pivotal Phase 3 trial. Interim analysis is expected to take place after 50% of the patients are enrolled. Cellerant has treated 75 patients in two Phase 1 dose escalation clinical trials with CLT-008. One trial tested CLT-008 in 45 leukemia patients following induction or consolidation chemotherapy. Several dose levels of CLT-008 were examined with or without Filgrastim. Data from the study show that CLT-008 was safe and well tolerated. Signals of clinical activity were observed with reductions in duration of fever (days in a febrile episode) and in the incidence of WHO Grade 2 mucositis in AML patients receiving induction therapy. Clinical data from this study were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco on December 7, 2014.

Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients with Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting

Cellerant Therapeutics Inc. announced that data from the Phase 1 clinical trial for CLT-008, a first-in-class, allogeneic, cell-based therapy for use in patients with acute myeloid leukemia (AML), will be presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014. Based on these positive Phase 1 results, Cellerant is initiating a multi-center, prospective, randomized Phase 2 clinical trial to demonstrate a decrease in risks of febrile episodes and infections related to chemotherapy treatment in AML. If successful, CLT-008 may also be applicable in many other clinical settings where chemotherapy-induced severe neutropenia is present.

Similar Private Companies By Industry

Company Name Region
Ambit Biosciences Corporation United States
Gene Express Inc. United States
Flagship Biosciences L.L.C. United States
Exemplar Genetics LLC United States
Reaction Biology Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cellerant Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at